# A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma

> **NCT04540211** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 461 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Tiragolumab
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Atezolizumab Matching Placebo
- **DRUG:** Tiragolumab Matching Placebo

## Key facts

- **NCT ID:** NCT04540211
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-30
- **Primary completion:** 2023-02-13
- **Final completion:** 2025-08-28
- **Target enrollment:** 461 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04540211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04540211, "A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04540211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*